Form 4: C4 Therapeutics Director Stephen Fawell Granted New Stock Options

C4 Therapeutics, Inc. Director Stephen Fawell was granted 35,500 stock options with an exercise price of $1.44, vesting by June 2026 or the next annual meeting.

Summary

• Stephen Fawell, a Director of C4 Therapeutics, Inc. (CCCC), acquired 35,500 stock options.
• The stock options have an exercise price of $1.44 per share.
• These options are scheduled to vest in full upon the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders.
• Vesting is contingent upon Mr. Fawell's continued service as a member of the Board.
• The options have an expiration date of June 17, 2035.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates standard corporate governance practices and aligns director incentives with company performance, without any negative implications.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.

Future Outlook

The stock options are set to vest in full by June 18, 2026, or earlier, upon the next annual meeting of stockholders, subject to the director's continued service.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation to align leadership interests with shareholder value creation.

Related Party Transactions

• The grant of stock options to a director is a transaction between the company and a related party (a member of its board), which is a standard form of compensation.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial interests with the long-term performance of the company's stock, potentially benefiting shareholders if the stock price increases.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest upon the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders, provided the recipient's continued service.

Key Dates

Keywords

C4 Therapeutics, CCCC, Stephen Fawell, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant